3D Medicines Extends HK$50 Million Note to Puxin, Flags Disclosure Lapse

3D Medicines, Inc. ( (HK:1244) ) has issued an update.

3D Medicines Inc., through its wholly owned Hong Kong subsidiary, has extended a HK$50 million unsecured short-term note to Puxin International Co., Ltd. at an unchanged annual coupon rate of 5.5%, pushing the maturity out to March 13, 2027 and funding the loan from internal idle funds. The company said the move aims to secure stable interest income and improve capital utilization to support research and development and working capital, while acknowledging a breach of Hong Kong Listing Rules disclosure requirements due to not reassessing transaction size amid market-cap fluctuations and outlining this as a discloseable transaction under the current rules.

The most recent analyst rating on (HK:1244) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.

More about 3D Medicines, Inc.

3D Medicines Inc. is a biopharmaceutical company focused on research, development and commercialization of innovative therapies, with operations including a wholly owned Hong Kong subsidiary. The group actively manages its capital through financial instruments to support its R&D investment and daily operating needs in the healthcare sector.

Average Trading Volume: 101,796

Technical Sentiment Signal: Sell

Current Market Cap: HK$1B

For detailed information about 1244 stock, go to TipRanks’ Stock Analysis page.